Startseite
Kongressberichte 2021
ESMO Congress 2021
Sunday, September 19
Proffered Paper sessions
Translational research
Translational research
1123O - Evaluation of cell-free DNA approaches for multi-cancer early detection
Minetta C. Liu, et al.
Conclusions
The strong correlation between cTF and cancer detection performance suggests that cLOD may be an attractive metric for comparing MCED test performance at equal specificity. Here, a WG methylation assay outperformed WGS or TS without needing additional WBC sequencing for CH. These data informed the design of a significantly improved targeted methylation MCED test for further CCGA substudies to support clinical use.
1757O - Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
Alexander N. Shoushtari, et al.
Conclusions
ctDNA was detected in most mUM pts, associated with tumor burden at BL and reduced in 70% of pts on tebe, despite a RECIST response rate of <10%. ctDNA reduction as early as 9 wks on tebe was strongly associated with improved OS, even in pts with RECIST PD or SD. Early ctDNA reduction may be a better surrogate of tebe efficacy than RECIST objective response in mUM.
1758O - Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
Kaysia Ludford, et al.
Conclusions
Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of radiographic and endoscopic response which has implications for organ-sparing strategies. Non-operative management of dMMR/MSI-H localized solid tumors should be further investigated.
https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1758O.html.pdf
1124O - Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides
Ingrid J. Garberis, et al.
Conclusions
DL applied to WSI could predict the risk of relapse in early ER+HER2- BC patients. Coupled to BV, our model could be a promising tool for treatment decision-making at low cost. Our next steps are to unravel the most predictive tiles to discover new biomarkers, and to develop novel models for prediction of relapse, as an alternative to onerous techniques such as immunohistochemistry or molecular tests.